The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study

N F Kalkers; F Barkhof; E Bergers; R van Schijndel; C H Polman

doi:10.1191/1352458502ms849xx

The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study

Mult Scler. 2002 Dec;8(6):532-3. doi: 10.1191/1352458502ms849xx.

Authors

N F Kalkers¹, F Barkhof, E Bergers, R van Schijndel, C H Polman

Affiliation

¹ Department of Neurology, Magnetic Resonance Centre for Multiple Sclerosis Research, VU Medical Center, PO Box 7057, Amsterdam 1007 MB, The Netherlands. [email protected]

PMID: 12474997
DOI: 10.1191/1352458502ms849xx

Abstract

Progressive axonal loss is the most likely pathologic correlate of irreversible neurologic impairment in primary progressive multiple sclerosis. In a run-in versus treatment trial, we show that the neuroprotective agent riluzole seems to reduce the rate of cervical cord atrophy and the development of hypointense T1 brain lesions on magnetic resonance imaging.

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Atrophy
Female
Humans
Magnetic Resonance Imaging*
Male
Middle Aged
Multiple Sclerosis, Chronic Progressive / drug therapy*
Multiple Sclerosis, Chronic Progressive / pathology*
Neuroprotective Agents / administration & dosage*
Neuroprotective Agents / adverse effects
Pilot Projects
Random Allocation
Riluzole / administration & dosage*
Riluzole / adverse effects
Treatment Outcome

Substances

Neuroprotective Agents
Riluzole